



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

08/495861

| | | | |
|--------------------|--------------|-----------------------|------------------|
| APPLICATION NUMBER | FIILING DATE | FIRST NAMED APPLICANT | ATTY. DOCKET NO. |
| 09/495,861 | 02/02/00 | PAGE | N 1430-234 |

HM22/0703
BIRCH STEWART KOLASCH BIRCH LLP
P O. BOX 747
FALLS CHURCH VA 22042-0747

| | |
|------------|--------------|
| ART UNREL. | PAPER NUMBER |
|------------|--------------|

Serial No. 09/495861

Art Unit 1644

DETAILED ACTION

1. Applicant's amendment, filed 2/2/00, is acknowledged.

Claims 2-8 15-16 and 26 have been canceled.

Claims 9, 10, 13, 17-20 and 22 have been amended.

Applicant's amendment, filed 5/18/00, is acknowledged.

Claims 27-47 have been added.

Applicant's amendment, filed 10/17/00, is acknowledged.

Claims 1-47 have been canceled.

Claims 48-78 have been added.

2. This application contains claims directed to the following patentably distinct species of the claimed Invention: wherein the human is afflicted with:

- A) a T cell disorder/ an autoimmune disease,
- B) cancer, or
- C) an infectious disease.

If a T cell disorder/ an autoimmune disease is elected; then this application contains claims directed to the following patentably distinct species of the claimed T cell disorders/ an autoimmune diseases, wherein the human is afflicted with:

- A) multiple sclerosis,
- B) GVHD,
- C) transplant rejection,
- D) psoriasis,
- E) diabetes,
- F) Sjorgrens disease,
- G) thyroid disease,
- H) myasthenia gravis,
- I) asthma,
- J) arthritis,
- K) lupus or
- L) vasculitis.

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

Serial No. 09/495861

Art Unit 1644

If cancer is elected; then this application contains claims directed to the following patentably distinct species of the claimed cancers, wherein the human is afflicted with:

- A) non-Hodgkins lymphoma or
- B) multiple myeloma.

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

If infectious diseases is elected; then this application contains claims directed to the following patentably distinct species of the claimed infectioius diseases, wherein the human is afflicted with:

- A) HIV or
- B) herpes.

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 48 and 58 are generic.

3. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Serial No. 09/495861
Art Unit 1644

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gabel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gabel

Phillip Gabel, PhD.
Primary Examiner
Technology Center 1600
July 2, 2001